EXACT Therapeutics: Strategic intent to delist the company’s shares from listing on Euronext Growth, Oslo
Oslo, Norway, 29 May 2026. EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, today announced that the Board proposes a delisting of the Company’s ordinary shares, which are currently listed on Euronext Growth Oslo.
The proposal is based on the Board’s assessment that a private company structure would better support EXACT Therapeutics’ next phase of development, improve its ability to access specialized international venture capital, and reduce the costs and obligations associated with a listing that provides limited liquidity for shareholders.
Trading activity in the Company’s shares has been very limited. From 1 January 2026 until 29 May 2026, a total of 4,698,607 shares were traded, representing approximately 4.21% of the total number of shares in the Company. During the same period, there were approximately 856 trades in the shares, corresponding to an average of approximately 8.5 trades per trading day. This year to date, there have been 16 trading days without any trades in the Company’s shares. Over the past five years, there has been no trading in the shares on approximately 50% of trading days.
The Company’s shareholder composition also resembles that of a private company, with a large percentage of the shares held by a limited number of shareholders. The 10 largest shareholders hold approximately 75% of the total number of shares, while the 20 largest shareholders hold approximately 87%. Due to the limited trading activity in the Company’s shares, the current shareholder structure is unlikely to materially change.
The Board further assesses that the Company has limited access to capital through Euronext Growth Oslo, and that the current listing is therefore not a suitable basis for attracting sizeable future financing. The Board believes that the Company’s future financing needs are more likely to be met through specialized international venture capital investors, and that the current listing may limit the Company’s ability to access such capital on attractive terms.
If a delisting is approved by the AGM on 12 June, the Company will apply to Euronext Growth Oslo to initiate the delisting process. If the company transitions to a private company structure, shareholders will retain their ownership, but the practical framework for trading will change. Following a delisting, the shares will no longer be admitted to trading on Euronext Growth Oslo. The Company will seek to ensure a clear and orderly process going forward, with relevant information to shareholders on the expected timeline, formal process and practical implications.
EXACT Therapeutics’ strategic focus remains unchanged. The Company will continue to prioritize the development of its proprietary drug, PS101, in locally advanced pancreatic cancer. The ENACT Phase 2 trial will continue according to plan, advancing toward per protocol safety read-out in mid-2026, interim read-out in end-2026, and key read-outs in 1H 2027.
About EXACT Therapeutics
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com
Forward looking statements:
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.